Endo International (NASDAQ:ENDP) Shares Gap Down to $3.96

Shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) gapped down prior to trading on Friday . The stock had previously closed at $3.82, but opened at $3.96. Endo International shares last traded at $4.15, with a volume of 69,769 shares.

Several equities research analysts recently weighed in on the company. Citigroup reduced their price target on Thor Industries from $78.00 to $70.00 in a research note on Monday, June 17th. Royal Bank of Canada cut Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $11.00 to $6.00 in a research note on Thursday. JPMorgan Chase & Co. upped their price target on Vermilion Energy from C$42.00 to C$43.00 in a research note on Monday, May 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price target (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Finally, ValuEngine cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company’s stock. Endo International currently has a consensus rating of “Hold” and an average target price of $11.57.

The business has a fifty day simple moving average of $4.56. The company has a market capitalization of $927.35 million, a price-to-earnings ratio of 1.42 and a beta of 1.15.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, May 9th. The company reported $0.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.11. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. The business had revenue of $720.00 million for the quarter, compared to the consensus estimate of $692.31 million. During the same period in the previous year, the company posted $0.67 earnings per share. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. Sell-side analysts predict that Endo International PLC will post 2.17 earnings per share for the current year.

In other news, Director Roger H. Kimmel sold 34,951 shares of the company’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $3.93, for a total transaction of $137,357.43. Following the transaction, the director now directly owns 148,309 shares of the company’s stock, valued at $582,854.37. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.80% of the company’s stock.

Several large investors have recently made changes to their positions in ENDP. Signition LP bought a new position in shares of Endo International during the first quarter valued at $139,000. Neuburgh Advisers LLC lifted its holdings in shares of Endo International by 13.9% during the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after purchasing an additional 3,036 shares in the last quarter. Factorial Partners LLC bought a new position in shares of Endo International during the first quarter valued at $193,000. First Quadrant L P CA lifted its holdings in shares of Endo International by 94.7% during the first quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock valued at $197,000 after purchasing an additional 11,926 shares in the last quarter. Finally, Flinton Capital Management LLC lifted its holdings in shares of Endo International by 13.9% during the fourth quarter. Flinton Capital Management LLC now owns 38,420 shares of the company’s stock valued at $280,000 after purchasing an additional 4,692 shares in the last quarter. 93.59% of the stock is currently owned by hedge funds and other institutional investors.

About Endo International (NASDAQ:ENDP)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: Trading signals using Bollinger bands

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.